Rebif (human IFN-β-1a) / EMD Serono 
Welcome,         Profile    Billing    Logout  

33 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rebif (human IFN-β-1a) / EMD Serono
2004-004903-39: A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs. Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis.

Ongoing
4
60
Europe
Mitoxantrone, Glatiramer Acetate, Interferon Beta 1a, , Injection*, Mitoxantrone, Copaxone, Rebif 44
The Walton Centre for Neurology and Neurosurgery
Early, active relapsing remitting Multiple Sclerosis (RRMS)
 
 
2006-000606-23: ?Post-authorization safety study to check the potential association between the safetyprofile of beta interferon 1a and the body mass index or pharmacodynamics during thetitration phase Estudio post-autorización de seguridad para determinar la posible asociación entre el perfil de seguridad de interferón beta-1a y el índice de masa corporal o los marcadores farmacodinámicos durante la fase de escalado de dosis.

Ongoing
4
100
Europe
Interferon-beta-1a, Solution for injection, Rebif 22 y 44 mcg
Merck, S.L., Merck, S.L.
Not applicalbe Esclerosis múltiple remitente recurrente, Not applicable Esclerosis múltiple remitente recurrente, Diseases [C] - Nervous System Diseases [C10]
 
 
2005-001008-37: Analysis of the antibody level against interferon beta before and after increase of dose in MS therapy

Ongoing
4
100
Europe
Rebif®, Not applicable, Rebif®, Rebif®
Sahlgrenska University Hospital
Multiple sclerosis
 
 
2007-004937-41: Etude du lien entre les marqueurs biologiques, la fatigue et les troubles cognitifs au cours de la sclérose en plaques de diagnostic récent et traitée par Interféron Bêta 1a SC (Rebif 44)

Ongoing
4
40
Europe
REBIF, REBIF, REBIF
Centre Hospitalier de Nancy
SLEROSE EN PLAQUE
 
 
2011-003570-89: The effect of interferon beta-1a treatment on adaptability of the brain in patients with MS Het effect van interferon beta-1a behandeling op het aanpassingsvermogen van de hersenen bij patienten met MS

Ongoing
4
100
Europe
Rebif, Rebif
VU University Medical Center, Merck Serono
Multiple sclerosis Multiple sclerose
 
 
2013-004626-28: Aivojen mikroglia-solujen aktivaation yhteys MS-tautiin

Ongoing
4
60
Europe
beetainterferoni -1a, Fingolimodi, REBIF, Gilenya, Avonex, Betaferon, Copaxone, Tysabri, Lemtrada, REBIF, Gilenya, Avonex, Betaferon, Copaxone, Tysabri, Lemtrada
Turku University Hospital, Novartis Pharma
Multiple sclerosis MS-tauti
 
 
2012-005450-30: Investigation of neutralising antibodies against interferon-beta in patients with multiple sclerosis, in order to find markers to predict the development of these antibodies and minimize the risk of ineffective therapy Erforschung der Bildung neutralisierender Antikörper gegen Interferon-beta bei Patienten mit Multipler Sklerose. Ziel ist es, Faktoren zu finden, mit denen man die Ausbildung solcher Antikörper vorhersagen und damit das Risiko einer unwirksamen Therapie vermindern kann

Ongoing
4
50
Europe
Avonex, Rebif, Betaferon, Extavia, Avonex, Rebif, Betaferon, Extavia
Medizinische Universität Innsbruck, ABIRISK
Development of neutralising antibodies against Interferon-beta in the treatment of multiple sclerosis Entwicklung neutralisierender Antikörper gegen Interferon-beta in der Therapie der Multiplen Sklerose
 
 
2017-002634-24: MultipleMS – a study with the aim to accelerate personalised medicine in multiple sclerosis. MultipleMS - en studie med syftet att utveckla precisionsmedicin för multipel skleros.

Ongoing
4
150
Europe
Infusion, Capsule, Tablet, Injection, Mabthera, Tysabri, Tecfidera, Gilenya, Copaxone, Betaferon, Extavia, Avonex, Rebif, Plegridy, Lemtrada, Aubagio
Karolinska Institutet, Department of Clinical Neuroscience, Karolinska Institutet
Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive), Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS), characterized by repeated episodes of inflammation in the CNS leading to various neurological symptoms., Diseases [C] - Nervous System Diseases [C10]
 
 
2016-004819-12: Discontinuation of first-line disease modifying treatment (DMT) in long-term full responders MS patients Sclerosi Multipla: effetti della sospensione del trattamento protratto con farmaci immunomodulanti di prima linea in pazienti "full responders"

Ongoing
4
300
Europe
Interferone Beta-1B, Inteferone Beta-1A, Glatiramer acetato, Interferon Beta-1a, [032166011], [033283045], [035418060], [034091165], Powder and solvent for solution for injection, Solution for injection, BETAFERON - 15 FLACONCINI 0.25 MG + 15 FLACONCINI 2 ML, AVONEX - 30 MCG (6 MILIONI UI) POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 4 FLACONI CON DISPOSITIVO BIOSET + 4 SIRINGHE PRERIEMPITE USO INTRAMUSCOLARE, COPAXONE - "40 MG/ML SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA" 12 SIRINGHE PRERIEMPITE DA 1 ML CON AGO, REBIF - 44 MCG(12 MILIONI UI) -SOLUZ INIETTABILE- USO SOTTOCUTANEO-PENNA PRERIEMPITA 0.5 ML (24 MILIONI UI/ML)12 PENNE PRERIEMPITE
OSPEDALE SAN RAFFAELE, AIFA - Italian Medicines Agency
Relapsing-Remitting multiple sclerosis (RR-MS), Sclerosi Multipla Recidivante Remittente, Relapsing-Remitting multiple sclerosis (RR-MS), Sclerosi Multipla Recidivante Remittente, Diseases [C] - Nervous System Diseases [C10]
 
 
DELIVER-MS, NCT03535298: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Active, not recruiting
4
800
Europe, US
Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod)
The Cleveland Clinic, University of Nottingham
Multiple Sclerosis, Relapsing-Remitting
07/27
09/30
ACTRN12608000435381: Comparison of Alemtuzumab and Rebif (registered trademark) Efficacy in Multiple Sclerosis, Study One

Active, not recruiting
3
581
 
Genzyme Corporation, Genzyme Corporation, Bayer Schering Pharma AG
Multiple Sclerosis, Relapsing-Remitting
 
 
ACTRN12608000426381: Comparison of Alemtuzumab and Rebif (registered trademark) Efficacy in Multiple Sclerosis, Study Two

Active, not recruiting
3
700
 
Genzyme Corporation, Genzyme Corporation, Bayer Schering Pharma AG
Multiple Sclerosis, Relapsing-Remitting
 
 
OPERA I, NCT01247324 / 2010-020337-99: A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Checkmark CMSC 2016: OPERA I and OPERA II
Jun 2016 - Jun 2016: CMSC 2016: OPERA I and OPERA II
Checkmark AAN 2016: OPERA I & OPERA II
Mar 2016 - Mar 2016: AAN 2016: OPERA I & OPERA II
Checkmark ACTRIMS Forum 2016: Multiple sclerosis (OPERA I & OPERA II)
More
Completed
3
821
Europe, US, RoW
Interferon beta-1a, Rebif, Ocrelizumab-matching placebo, Ocrelizumab, RO4964913, Interferon beta-1a-matching placebo
Hoffmann-La Roche
Relapsing Multiple Sclerosis
04/15
12/22
OPERA II, NCT01412333 / 2010-020315-36: A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Checkmark CMSC 2016: OPERA I and OPERA II
Jun 2016 - Jun 2016: CMSC 2016: OPERA I and OPERA II
Checkmark AAN 2016: OPERA I & OPERA II
Mar 2016 - Mar 2016: AAN 2016: OPERA I & OPERA II
Checkmark ACTRIMS Forum 2016: Multiple sclerosis (OPERA I & OPERA II)
More
Completed
3
835
Europe, Canada, US, RoW
Interferon beta-1a, Rebif, Ocrelizumab-matching placebo, Ocrelizumab, RO4964913, Interferon beta-1a-matching placebo
Hoffmann-La Roche
Relapsing Multiple Sclerosis
05/15
12/22
2006-004937-13: multicentee randomized controlled study of azathioprine versus iterferon beta in relapsing remitting multiple sclerosis

Ongoing
3
360
Europe
AZATIOPRINA HEX. 50CPR 50MG BL, REBIF SC 12SIR 6000000UI 22MCG, BETAFERON SC 15F 0,25MG 15SIR, REBIF SC 12SIR 12000000UI44MCG, AVONEX IM 4SIR 30MCG/0,5ML 4AG, AZATIOPRINA HEX. 50CPR 50MG BL, REBIF SC 12SIR 6000000UI 22MCG, BETAFERON SC 15F 0,25MG 15SIR, REBIF SC 12SIR 12000000UI44MCG, AVONEX IM 4SIR 30MCG/0,5ML 4AG
Universita di Firenze
patients with relapsing remitting multiple sclerosis
 
 
2012-005086-12: Study to investigate the ability of a blood-derived score to select patients with relapsing multiple sclerosis who benefit from treatment with human immune globulin

Ongoing
3
81
Europe
Rebif 44 micrograms, Betaferon 250 microgram/ml, Extavia 250 microgram/ml, Octagam 50 mg/ml, Copaxone 20 mg/ml, Rebif 44 micrograms, Betaferon 250 microgram/ml, Extavia 250 microgram/ml, Octagam 50 mg/ml, Copaxone 20 mg/ml, Rebif 44 micrograms, Betaferon 250 microgram/ml, Extavia 250 microgram/ml
Octapharma AG, Octapharma AG
relapsing multiple sclerosis
 
 
2018-001292-21: Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Arrêt des traitements de fond à visée immunologique chez les patients de plus de 50 ans ayant une sclérose en plaques secondairement progressive

Not yet recruiting
3
250
Europe
AVONEX, BETAFERON, EXTAVIA, REBIF, PLEDIGRY, COPAXONE, AUBAGIO, TECFIDERA, GILENYA, TYSABRI, IMUREL, NOVATREX, CELLCEPT, ENDOXAN, L03 AB 08, Concentrate for solution for injection, Powder for solution for injection, Solution for injection, Solution for injection in pre-filled syringe, Tablet, Capsule, Concentrate for solution for infusion
CHU de Rennes, CHU de Rennes
Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Diseases [C] - Nervous System Diseases [C10]
 
 
2020-002060-31: An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care Mezinárodní randomizovaná studie další léčby COVID-19 u hospitalizovaných pacientů, kteří jsou léčeni standardní péčí.

Ongoing
3
100000
Europe
remdesivir, Lyophilisate for solution for infusion, Coated tablet, Powder and solution for solution for injection, Kaletra, Rebif, Plaquenil
Masaryk University, World Health Organisation, Masaryk University
COVID-19 COVID-19, COVID-19 COVID-19, Diseases [C] - Virus Diseases [C02]
 
 
DisCoVeRy, NCT04315948 / 2020-000936-23: Trial of Treatments for COVID-19 in Hospitalized Adults

Hourglass Dec 2021 - Dec 2021 : Data from DisCoVeRy trial for treatment of COVID-19 in hospitalized adults
Completed
3
1552
Europe
Remdesivir, Lopinavir/ritonavir, Interferon Beta-1A, Hydroxychloroquine, Standard of care, AZD7442, Placebo
Institut National de la Santé Et de la Recherche Médicale, France
Corona Virus Infection
07/22
09/23
NCT03283397: A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS

Terminated
3
301
RoW
EK-12, INF beta-1a
Bosnalijek D.D, MonitorCRO
Multiple Sclerosis, Relapsing-Remitting
07/23
07/23
MIST, NCT03133403 / 2012-004165-41: Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy

Recruiting
2/3
5
Europe
Tecfidera (BG12), Gilenya, fingolimod, Tysabri®, natalizumab, Avonex/Betaseron/Copaxone/Rebif, (Avonex®, Betaseron®, Copaxone®, Rebif®), Hematopoietic stem cell transplantation (HSCT)
Sheffield Teaching Hospitals NHS Foundation Trust
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
12/21
12/21
ACTRN12622000258752: INFINiTE-CV2 Phase IIa Trial: INterFeron type 1 Intra-Nasal gel Therapy for Early treatment of SARS-CoV2 (COVID-19)

Not yet recruiting
2
100
 
IntraVital, IntraVital Pty Ltd
COVID-19
 
 
2008-005656-24: ENSAYO CLÍNICO SOBRE LA EVOLUCIÓN Y EL IMPACTO DEL TRATAMIENTO FARMACOLÓGICO EN LA PERDIDA AXONAL PROGRESIVA EN PACIENTES QUE CON ESCLEROSIS MÚLTIPLE QUE HAN PRESENTADO UN PRIMER EPISODIO DESMIELINIZANTE

Ongoing
2
20
Europe
REBIF 22 microgramos solución inyectable, REBIF 22 microgramos solución inyectable
Dra. Rosario Blasco
Primer episodio desmielinizante con criterios de esclerosis múltiple (EM) confirmada por laboratorio que no haya consistido en neuritis óptica y que no tengan criterios de mal pronóstico definidos como: 9 ó +lesiones y/o lesiones que capten Gd, afectación cerebelosa, EDSS>2 a las tres semanas del inicio del episodio.
 
 
2020-003872-42: Antiviral and Immunomodulatory Interferon-Beta in high-risk COVID-19 patients Valutazione dell’attività antivirale e immunomodulatoria di Interferone-Beta in pazienti COVID-19 anziani

Ongoing
2
60
Europe
Interferon beta-1a, [IFNb], Solution for injection, REBIF - 22 MCG/0.5 ML - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - CARTUCCIA (VETRO) - 1.5 ML (12 MILIONI UI/ML) 4 CARTUCCE
Istituto di Farmacologia Traslazionale - CNR, Regione Lazio, Istituto Nazionale per le malattie infettive "Lazzaro Spallanzani", Merck Healthcare KGaA, Istituto Superiore di Sanità, Istituto di Farmacologia Traslazionale - CNR
SARS-CoV 2 infection characterized by a National Early Warning Score lower or equal to 2 and symptoms present for less than 7 days Infezione da virus SARS-CoV 2 con sintomatologia presente da meno di 7 giorni e punteggio minore o uguale a 2 nella National Early Warning Score (NEWS), Early SARS-CoV 2 infection characterized by mild COVID-19 symptoms Stato iniziale di infezione da virus SARS-CoV 2 con sintomi lievi di COVID-19, Diseases [C] - Virus Diseases [C02]
 
 
NCT05298670: Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients

Recruiting
2
80
RoW
MetFORMIN 1000 Mg Oral Tablet, Cidophage ®1000 mg tablets, CID, Giza, Egypt) tablet and Rebiff ® 44mcg or Avonex®, Interferon beta-1a, Rebiff ® 44mcg or Avonex®
German University in Cairo
Multiple Sclerosis
02/23
03/23
TLV-0326-24, NCT06510426: Early Interferon-beta Treatment for West-Nile Virus Infection

Recruiting
2
100
RoW
Rebif 44 MCG Per 0.5 ML Prefilled Syringe, Saline
Tel-Aviv Sourasky Medical Center
West Nile Virus, West Nile Fever Encephalitis, West Nile Fever Myelitis, West Nile Fever With Other Complications
07/25
12/25
NCT04079088: Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)

Withdrawn
2
300
NA
Placebo, BIIB061, Interferon-beta1, Avonex, Plegridy, Betaferon/Betaseron, Extavia, or Rebif, Glatiramer acetate, Copaxone, Glatopa
Biogen
Relapsing Multiple Sclerosis
09/24
09/24
NPC-Nivo, NCT06019130: Nivolumab in Children and Adults With Nasopharyngeal Carcinoma

Recruiting
2
57
Europe
Nivolumab, Opdivo, Cisplatin, Cisplatin Teva, 5-Fluorouracil, Fluorouracil-GRY, Gemcitabine, Gemcitabin-GRY, Radiotherapy, Interferon beta-1a, Rebif, MRI, PET, Patient-Reported Outcomes
German Society for Pediatric Oncology and Hematology GPOH gGmbH, Deutsche Krebshilfe e.V., Bonn (Germany)
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharyngeal Neoplasms, Nasopharynx Cancer
01/26
01/28
NCT02330393: Localized Radiation Therapy or Recombinant Interferon Beta and MSB0010718C With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma

Not yet recruiting
1/2
20
US
Anti-PD-L1 Monoclonal Antibody MSB0010718C, MSB0010718C, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, RT, Recombinant Interferon Beta, Betantrone, Betaseron, Feron, IFN-B, Rebif, MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells, MCPyV TAg-specific polyclonal autologous CD8-positive T cells, Laboratory Biomarker Analysis
Fred Hutchinson Cancer Research Center, National Cancer Institute (NCI)
Merkel Cell Polyomavirus Infection, Stage IV Merkel Cell Carcinoma
01/19
 
NCT05936229: Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Withdrawn
1/2
24
US
Interferon Beta-1A, 145258-61-3, Avonex, BG9418, Rebif, Recombinant interferon beta-1a, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Computed Tomography, CAT Scan, Computed Axial Tomography, Computerized axial tomography (procedure), Positron Emission Tomography, Pet Scan, Positron emission tomography (procedure), Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Lumbar Puncture, LP, spinal tap, Bone Marrow Aspiration, Bone Marrow Biopsy, Biospecimen Collection, Biological Sample Collection, Biopsy, BIOPSY_TYPE, Bx
Fred Hutchinson Cancer Center, Faron Pharmaceuticals Ltd
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
10/27
10/27
ACTRN12622000094774: INFINiTE-CV2 Phase I Trial: INterFeron type 1 Intra-Nasal gel Therapy for Early treatment of SARS-CoV2 (COVID-19)

Not yet recruiting
1
20
 
Dr Edmund Lau, IntraVital
COVID-19
 
 
TREAT-MS, NCT03500328: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Recruiting
N/A
900
US
Natalizumab, Alemtuzumab, Ocrelizumab, Rituximab, Cladribine, Ofatumumab, Ublituximab-xiiy, Tysabri, Lemtrada, Ocrevus, Rituxan, Mavenclad, Kesimpta, Briumvi, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso
Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Multiple Sclerosis, Relapsing-Remitting
08/25
08/25
INFORM, NCT06053749: An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden

Active, not recruiting
N/A
4
Europe
Avonex (IFNβ-1-a, Biogen Netherlands B.V), Rebif (IFNβ-1-a, Merck Europe B.V.), Extavia (IFNβ-1-b, Novartis Europharm Limited), Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG), Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V), MS disease modifying drugs (MSDMDs)
Bayer, Biogen Netherlands B.V, Novartis Europharm Limited, Merck Europe B.V.
Multiple Sclerosis (MS)
03/26
03/26

Download Options